2019年6月10日新泽西州Freehold——国际领先的细胞生物技术公司Avalon Globocare（纳斯达克：AVCO）今天宣布，该公司在临床级干细胞外泌体的生产标准化方面完成了重要里程碑。这一进展是公司之前宣布的与康奈尔医学院（Weill Cornell Medicine） Yen-Michael Hsu教授联合开发项目的直接成果。该标准化流程是在康奈尔医学院cGMP认证的细胞实验室内共同开发和操作的，该实验室同时也具备细胞治疗认证基金会（FACT）、美国血库协会（AABB）、CAP以及CLIA的认证。
Avalon将于2019年6月15日第二届中国成都国际医美产业大会（亚洲最大行业会议）中，发布其基于外泌体的产品计划，包括具有知识产权的临床级外泌体添加成分（“ACTEX“）的系列护肤及疤痕修复产品。除了该产品，Avalon同时还在推进其他临床级干细胞外泌体的制备标准化，包括针对血管/骨科再生和纤维化疾病治疗的AVA-202、AVA-203等临床方案。
Avalon GloboCare的CEO兼总裁David Jin博士表示： “很高兴我们完成了外泌体项目中如此重要的发展里程碑，我们期待通过这一进展，能进一步加速我们基于外泌体的临床应用，并推动一系列外泌体产品的商业化。”
Avalon GloboCare Corp.（NASDAQ: AVCO）是一家国际领先的细胞技术开发公司，致力于开发和转化具有创新性、变革性的外泌体和细胞治疗技术。Avalon也提供战略咨询和技术合作服务，以协助促进其客户在技术开发领域的发展，提高其在本国和全球医疗市场的竞争力。通过子公司GenExosome Technologies Inc.和Avactis Biosciences Inc.，Avalon在基于外泌体的诊断(“液体活检”) 、细胞免疫治疗(包括CAR-T/CAR-NK) 和再生医学领域建立了领先地位。
Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of the press release.
